Here, we present — for the first time to our knowledge in the obesity arena — in vivo, in vitro, functional, and mechanistic data that demonstrate the therapeutic utility of a compound directed against S6K1, the LY2584702 tosylate (hereafter referred to as LY), an oral inhibitor initially developed for the treatment of solid tumors (19). The gene discussed is RPS6KB1; the disease is Obesity.